Otsuka Pharmaceutical Development & Commercialization, Inc.
Clinical trials sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., explained in plain language.
A subsidiary of Otsuka Holdings, focused on developing and commercializing pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug VIS171 enters human trials for lupus, hair loss, and kidney disease Results expected Oct 2026 (estimated)
- New schizophrenia pill shows promise in major trial Results expected Oct 2026 (estimated)
- New drug interaction study launches for repinatrabit Results expected Nov 2026 (estimated)
- Study aims to tailor PKU drug dosing for patients with organ impairment Results expected Feb 2027 (estimated)
- New shot could tame Sjögren's Flare-Ups Results expected Mar 2027 (estimated)
-
Alzheimer's agitation drug trial halted early
Disease control Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce agitation in people with Alzheimer's dementia over the long term. It was an extension of earlier studies, enrolling over 1,100 participants who had already completed a prior trial. However, the study was ter…
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Brain scan study tests new Drug's target binding in healthy volunteers
Knowledge-focused Stopped earlyThis early-stage study involves 18 healthy men to see how well the experimental drug MSP-2020 attaches to serotonin receptors in the brain. Researchers will also measure how much drug stays in the blood and check for side effects. The goal is to understand the drug's activity in …
Phase 1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC